A closer look at the staging of soft tissue sarcomas in an era of personalized medicine

We read with enthusiasm the editorials by Rick Hass and William Tseng in response to our recently published manuscript, “A novel, simplified, externally validated staging system for truncal/extremity soft tissue sarcomas: An analysis of the US Sarcoma Collaborative database” (1). These editorials, along with a considerable array of recent publications, review articles, and other editorials over the past few years, represent a re-invigorated interest for this rare, and previously somewhat ignored, malignancy amongst the oncology community.